Investor Overview

Investor Presentation
Financial News
Aug 4, 2020

Further advances in recurrent glioblastoma program including submission of End of Phase 2 (“EOP2”) meeting package for MDNA55 EOP2 meeting scheduled for 29th September, 2020 with FDA input...

Jun 11, 2020

Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX: MDNA) (OTCQB: MDNAF), a clinical stage immuno-oncology company, today announced that Dr. Fahar Merchant, President, CEO and...

Stock Quote
TSXMDNA
Stock Chart
TSXMDNA
Upcoming Events
No events to display
Investor Contact
For more investor information, Please contact:
 
Elizabeth Williams, Chief Financial Officer
 
 
Email Alerts
* Required Fields